臨床データの収集・解析とともに、Parkinson病(Parkinson’s disease: PD)患者で問題となる精神症状である衝動制御障害(Impulsive control disorder: ICD)のうち主にドパミン調節障害(Dopamine dysregulation syndrome: DDS)、アパシーの病態を再現したモデルマウスを作製し、それらを用いて病態解明や治療法の検討を行う。
【代表者】
依存症プロジェクト 藤田雅代
【共同研究者】
都立神経病院 脳神経内科 興津雅人
【学会発表】
The 8th Congress of the Asian College of Neuropsychopharmacology (AsCNP 2023) 演題名:Dopamine dysregulation syndrome-like behavior in bilateral dorsal striatum 6-hydroxydopamine lesioned Parkinson‘s disease model mice. 2023年9月22~24日(ポスター発表) PDF
第64回日本神経学会総会
演題名:Dopamine dysregulation syndrome-like behavior in bilateral dorsal striatum 6-hydroxydopamine lesioned Parkinson's disease model mice. 2023年5月31日(ポスター発表)PDF
35th World Congress Collegium Internationale Neuro-Psychopharmacologicum (CINP 2024)
演題名:Transversal investigation of apathic behaviors in a Parkinson’s disease mouse model with 6-hydroxydopamine lesioning in the bilateral dorsal striatum. 2024年5月25日(ポスター発表)
PDF
【受賞歴】
JSNP Excellent Presentation Award for AsCNP 2023 受賞
ORIGINAL RESEARCH article Front. Neurol., 11 March 2020 Sec. Applied Neuroimaging Volume 11 - 2020 | https://doi.org/10.3389/fneur.2020.00179 Assessment and Rating of Motor Cerebellar Ataxias With the Kinect v2 Depth Sensor: Extending Our Appraisal
Int. J. Mol. Sci. (2022) 23, 7436
Therapeutic Effects of Quetiapine and 5-HT1A Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice
Molecular Brain (2020)13:126 Increase in excitability of hippocampal neurons during novelty-induced hyperlocomotion in dopamine-deficient mice
【学会発表】
第60回日本神経学会学術大会(2019/5/22-25)Analysis of neuronal excitability in hyperlocomotive dopamine deficient mice
The 10th IBRO World Congress of Neuroscience(2019/9/21-25)Effects of serotonergic drugs on dopamine-deficient mice.
The 6th Asian College of Neuropsychopharmacology(2019/10/11-13)Analysis of the effects of serotonin related drugs on hyperlocomotion in dopamine-deficient mice.
第61回日本神経学会学術大会(2020/8/31-9/2)Effects of serotonergic drugs on hyperlocomotive dopamine-deficient mice
Neurology meeting in 北多摩 (2021/9/17) 初回入院後の経過からパーキンソン病精神症状を考える
7th Congress of AsCNP (2021/10/22-23) 5-HT1A agonist improves psychiatric hyperlocomotion in a mouse model of Parkinson’s disease caused by dopamine deficiency.
60th Annual Meeting of ACNP (2021/12/5-8) 5HT1A agonist is involved in psychiatric symptoms in a mouse model of Parkinson's disease, and suppressing activity of the median raphe nucleus may be the key.
The Lancet Summit (2021/12/14-16) The 5HT-1A receptor targeted drugs may help to prevent the appearance of psychosis with Parkinson’s disease.
Ochiai Y, Fujita M, Hagino Y, Kobayashi K, Okiyama R, Takahashi K, Ikeda K
The therapeutic effects of 5-HT1A receptor agonist on the psychomotor hyperactivity in dopamine-deficient mice.
33rd CINP World Congress of Neuropsychopharmacology, Virtual & Taipei, Taiwan